Background: The Barrier Is Not Just the Tumor—It’s the Ecosystem

CAR T-cell therapy has transformed hematologic malignancies, delivering durable remissions in diseases once considered refractory.¹ In solid tumors, however, progress has been limited—not for lack of effort, but because the biological problem is fundamentally different.

Two barriers have persisted. First, antigen heterogeneity enables tumor escape, undermining single-target strategies. Second, the tumor microenvironment (TME) imposes both physical exclusion and active immunosuppression, preventing sustained CAR T-cell activity.^2,3

Historically, these challenges have been approached separately: combinatorial targeting for antigen escape, and checkpoint blockade or stromal modulation for TME resistance. What has remained elusive is a single target that addresses both simultaneously.

uPAR (encoded by PLAUR) emerges as a compelling candidate. Long recognized as a marker of senescent and pro-fibrotic cells, uPAR has been implicated in wound-healing and fibrosis programs that tumors co-opt during progression. Prior work demonstrated that uPAR-directed CAR T cells could eliminate senescent cells and reverse fibrosis, establishing proof of concept for senolytic CAR T therapy.⁴

The key insight driving this study is that tumors do not exist in isolation—they construct a shared, senescence-associated ecosystem spanning malignant cells and their supporting stroma. uPAR marks that ecosystem.

Zhang, Filliol, and colleagues now extend this concept into oncology, demonstrating its relevance across tumor types and its therapeutic vulnerability.⁵

The Study: Targeting a Cell State, Not a Cell Type

This work represents a conceptual shift.

Using TCGA data (n = 10,071 across 14 cancer types), multiplex immunofluorescence, and extensive preclinical modeling, the investigators redefine uPAR not as a lineage marker, but as a marker of a convergent cell state—one characterized by senescence, EMT, fibrosis, and inflammatory signaling.⁵

This distinction is critical. Cell types can vary across tumors; cell states driven by shared oncogenic programs do not.

Human uPAR CAR T cells were engineered to recognize a membrane-stable form of uPAR resistant to proteolytic shedding—a key limitation of earlier approaches. A functional threshold of approximately 1,500 surface molecules per cell was identified as necessary for effective cytotoxicity, introducing a quantitative framework for target engagement and potential patient selection.⁵

Efficacy was evaluated across multiple systems, including organoids and in vivo models of lung, pancreatic, ovarian, and colorectal cancers, with particular attention to metastatic disease.

Key Findings

uPAR Marks a Convergent, High-Risk Tumor State

uPAR expression was elevated in 12 of 14 cancer types and strongly associated with TP53 loss and RAS pathway activation—2 of the most pervasive and therapeutically challenging alterations in oncology.⁵

These tumors exhibited transcriptional programs linked to EMT, inflammation, and fibrosis, reflecting a highly plastic and aggressive phenotype.

Mechanistically, this aligns with developmental models in which KRAS activation induces a progenitor-like uPAR-positive state normally constrained by p53. Loss of p53 permits expansion of this state, embedding it within advanced disease biology.⁵

Importantly, uPAR expression extended beyond tumor cells to include cancer-associated fibroblasts and immunosuppressive myeloid populations—capturing the full architecture of the tumor-supporting niche.

Dual Compartment Elimination: Tumor and Stroma

uPAR CAR T cells eliminated both malignant cells and the stromal compartments that sustain them.⁵

This dual targeting represents a meaningful advance. Prior strategies have either targeted tumor cells while leaving the suppressive niche intact, or disrupted stroma without directly engaging tumor burden. uPAR CAR T cells do both—simultaneously.

Across multiple tumor models, this translated into durable regressions and, notably, eradication of systemic metastases—a critical endpoint given that metastatic disease drives the majority of cancer mortality.⁵

Senescence as a Therapeutic Lever

One of the most clinically actionable findings is the synergy with senescence-inducing therapies.

Cisplatin, a standard chemotherapeutic agent, induces a senescent phenotype and upregulates uPAR expression, converting previously low-expressing cells into CAR T–susceptible targets.⁵

This suggests a practical and immediately translatable strategy: chemotherapy as priming, rather than competition, for cellular therapy.

Preserved Activity Without Sustained Myelosuppression

Despite targeting a broadly expressed stress-response marker, uPAR CAR T cells maintained anti-tumor efficacy in humanized models without sustained myelosuppression.⁵

This appears to reflect a surface density threshold effect—normal tissues express uPAR below the level required for efficient CAR T-mediated killing, preserving a therapeutic window.

Clinical and Translational Perspective

This work reframes the development paradigm for solid tumor CAR T therapy. Rather than pursuing tumor-specific antigens, it introduces a state-centric targeting strategy—one anchored in conserved biological programs (TP53 loss, RAS activation, EMT) that are less susceptible to escape.

The breadth of uPAR expression supports a histology-agnostic approach, with immediate relevance to high-need settings such as pancreatic cancer, ovarian cancer, and KRAS-mutant lung adenocarcinoma.

Equally important is the ability to dismantle the tumor ecosystem itself. By eliminating both malignant cells and their supporting stroma, uPAR CAR T cells may overcome a central limitation of prior approaches: the rapid reconstitution of an immunosuppressive niche following partial tumor clearance.

The chemotherapy synergy further enhances feasibility, aligning this strategy with existing treatment paradigms and enabling rational sequencing in clinical trials.

Safety Considerations and Open Questions

The central challenge moving forward will be safety.

uPAR is expressed at low levels in normal tissues, particularly in myeloid cells and during wound repair. Whether transient depletion of these populations will translate into clinically meaningful toxicity remains unknown.

The proposed density threshold offers a promising framework but requires validation in human studies.

Additional questions include:

• Durability of responses and long-term ecosystem reconstitution
• Biomarker strategies to identify uPAR-high tumor states
• Optimal sequencing with chemotherapy or other priming agents
• Translation of preclinical safety signals into human immunobiology

As with all solid tumor CAR T approaches, the limitations of preclinical models must be acknowledged.

What Comes Next

Early-phase clinical trials will need to define both safety and patient selection.

The integration of senescence-inducing therapies should be prioritized, given strong mechanistic rationale and immediate clinical applicability. Tumor types with high uPAR expression and limited options—ovarian, pancreatic, and lung—represent logical entry points.

Beyond oncology, the broader implications are notable. uPAR-directed targeting of senescent ecosystems may extend into fibrosis and age-related disease, positioning this work at the intersection of cancer biology and regenerative medicine.

Bottom Line

Zhang, Filliol, and colleagues demonstrate that uPAR defines a convergent, senescence-associated tumor ecosystem—and that targeting this state with CAR T cells enables simultaneous elimination of tumor and stromal compartments across diverse solid tumors.

The implication is a paradigm shift: the future of CAR T therapy in solid tumors may depend less on identifying the perfect antigen, and more on targeting the shared biological state that tumors are compelled to adopt.

References

1. Neelapu SS, Locke FL, Bartlett NL, et al. Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma. N Engl J Med. 2017;377(26):2531–2544. doi:10.1056/NEJMoa1707447
2. Majzner RG, Mackall CL. Tumor antigen escape from CAR T-cell therapy. Cancer Discov. 2018;8(10):1219–1226. doi:10.1158/2159-8290.CD-18-0442
3. Pittet MJ, Michielin O, Migliorini D. Clinical relevance of tumour-associated macrophages. Nat Rev Clin Oncol. 2022;19(7):402–421. doi:10.1038/s41571-022-00620-6
4. Amor C, Feucht J, Leibold J, et al. Senolytic CAR T cells reverse senescence-associated pathologies. Nature. 2020;583(7814):127–132. doi:10.1038/s41586-020-2403-9
5. Zhang Z, Filliol A, et al. A convergent uPAR-positive tumor ecosystem creates broad vulnerability to CAR T cell therapy. Cell. 2026. doi:10.1016/j.cell.2026.03.002